Why do tb patients take vitamin b6

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: TB patients take vitamin B6 (pyridoxine) primarily to prevent peripheral neuropathy caused by the anti-TB drug isoniazid. Isoniazid interferes with vitamin B6 metabolism, and supplementation of 25-50 mg daily is recommended during treatment. This practice has been standard since the 1950s when isoniazid was introduced, reducing neuropathy incidence from 20% to less than 1% in treated patients.

Key Facts

Isoniazid, a first-line TB drug since 1952, causes vitamin B6 deficiency by inhibiting pyridoxal phosphate formation
Without supplementation, 10-20% of patients on isoniazid develop peripheral neuropathy
WHO recommends 25-50 mg pyridoxine daily during TB treatment, with higher doses (100 mg) for high-risk groups
Vitamin B6 supplementation reduces neuropathy risk to less than 1% in compliant patients
Isoniazid remains essential despite this side effect, curing 90-95% of drug-sensitive TB cases when properly administered

Overview

Tuberculosis treatment has included vitamin B6 supplementation since the 1950s when isoniazid became a first-line medication. Isoniazid, discovered in 1951 and approved in 1952, revolutionized TB therapy but was soon found to cause peripheral neuropathy in 10-20% of patients. Researchers discovered this resulted from isoniazid interfering with vitamin B6 metabolism, specifically by inhibiting the formation of pyridoxal phosphate, the active coenzyme form. By 1954, studies showed that concurrent pyridoxine administration prevented this neurological complication. Today, the World Health Organization's 2022 TB treatment guidelines recommend routine B6 supplementation during isoniazid-containing regimens. This practice has become standard globally, with an estimated 10 million TB patients receiving isoniazid-based therapy annually, nearly all with B6 co-administration to ensure treatment completion and prevent disabling side effects.

How It Works

Isoniazid chemically resembles pyridoxine (vitamin B6) and competes with it for binding to enzymes involved in neurotransmitter synthesis. Specifically, isoniazid inhibits pyridoxal kinase, the enzyme that converts pyridoxine to pyridoxal phosphate (PLP). PLP serves as a cofactor for over 100 enzymes, including those producing neurotransmitters like GABA, serotonin, and dopamine. Without adequate PLP, nerve function deteriorates, causing symmetrical numbness, tingling, and pain in hands and feet - classic peripheral neuropathy symptoms. Vitamin B6 supplementation provides sufficient substrate to overcome this competitive inhibition. The standard 25-50 mg daily dose maintains normal PLP levels despite isoniazid's interference. Higher doses (up to 100 mg) are used for high-risk patients including those with diabetes, HIV, alcoholism, or malnutrition who have increased susceptibility to neuropathy.

Why It Matters

This simple supplementation strategy has profound public health significance. Without B6, neuropathy causes many patients to abandon TB treatment, leading to treatment failure, drug resistance, and continued transmission. Isoniazid remains crucial because it kills 90% of TB bacilli within days and cures 90-95% of drug-sensitive cases when taken properly. B6 co-administration ensures treatment completion, preventing multidrug-resistant TB development. Economically, B6 costs pennies per day compared to thousands for treating drug-resistant TB. The practice exemplifies how understanding drug-nutrient interactions can transform a medication from problematic to essential, enabling isoniazid's continued use in global TB elimination efforts targeting zero deaths by 2030.